Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

LaTonya J Hickson,Larissa G P Langhi Prata,Shane A Bobart,Tamara K Evans,Nino Giorgadze,Shahrukh K Hashmi,Sandra M Herrmann,Michael D Jensen,Qingyi Jia,Kyra L Jordan,Todd A Kellogg,Sundeep Khosla,Daniel M Koerber,Anthony B Lagnado,Donna K Lawson,Nathan K LeBrasseur,Lilach O Lerman,Kathleen M McDonald,Travis J McKenzie,João F Passos,Robert J Pignolo,Tamar Pirtskhalava,Ishran M Saadiq,Kalli K Schaefer,Stephen C Textor,Stella G Victorelli,Tammie L Volkman,Ailing Xue,Mark A Wentworth,Erin O Wissler Gerdes,Yi Zhu,Tamara Tchkonia,James L Kirkland

DOI: https://doi.org/10.1016/j.ebiom.2019.08.069

IF: 11.205

EBioMedicine

Abstract:Background: Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q), selectively eliminate senescent cells by transiently disabling pro-survival networks that defend them against their own apoptotic environment. In the first clinical trial of senolytics, D + Q improved physical function in patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease, but to date, no peer-reviewed study has directly demonstrated that senolytics decrease senescent cells in humans. Methods: In an open label Phase 1 pilot study, we administered 3 days of oral D 100 mg and Q 1000 mg to subjects with diabetic kidney disease (N = 9; 68·7 ± 3·1 years old; 2 female; BMI:33·9 ± 2·3 kg/m2; eGFR:27·0 ± 2·1 mL/min/1·73m2). Adipose tissue, skin biopsies, and blood were collected before and 11 days after completing senolytic treatment. Senescent cell and macrophage/Langerhans cell markers and circulating SASP factors were assayed. Findings: D + Q reduced adipose tissue senescent cell burden within 11 days, with decreases in p16INK4A-and p21CIP1-expressing cells, cells with senescence-associated β-galactosidase activity, and adipocyte progenitors with limited replicative potential. Adipose tissue macrophages, which are attracted, anchored, and activated by senescent cells, and crown-like structures were decreased. Skin epidermal p16INK4A+ and p21CIP1+ cells were reduced, as were circulating SASP factors, including IL-1α, IL-6, and MMPs-9 and -12. Interpretation: "Hit-and-run" treatment with senolytics, which in the case of D + Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans. FUND: NIH and Foundations. ClinicalTrials.gov Identifier: NCT02848131. Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents.